No big-bang moment: An AI-supported future in pharma will take time
Thomas Swalla, CEO of Dotmatics, discusses in a Fox News article how AI is poised to transform drug discovery by potentially saving billions and speeding up therapy delivery, while emphasizing that despite industry readiness, significant and growing barriers mean progress will be gradual through cumulative small advances rather than an immediate breakthrough.
What will the world of AI-powered drug discovery look like?
Authored by Thomas Swalla, CEO of Dotmatics and published by Fox News
This piece provides an industry insider's perspective on the role of AI in life sciences, specifically focusing on drug development. It explores how AI is positioned to reshape the drug development process, with the potential to save billions of dollars and accelerate the delivery of life-changing therapies to patients.
Key insights from Thomas Swalla, CEO of Dotmatics:
- Why the industry is (finally) set up to succeed
- What barriers remain — and why they’re getting bigger
- How small wins add up to transformative change
For further reading, the full article is available on Fox News.
Related
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
How AI is Transforming Drug Discovery
Dotmatics executives Kalim Saliba and Steve Tharp explain in an NBC News Boston feature how AI is revolutionizing drug discovery by enabling researchers to navigate complex data more efficiently, significantly reducing development time and costs, and accelerating the creation of safer, personalized medicines.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.